MSH3 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P20585 |
---|---|
Clone Names | 100617160 |
Gene ID | 4437 |
---|---|
Other Names | DNA mismatch repair protein Msh3, hMSH3, Divergent upstream protein, DUP, Mismatch repair protein 1, MRP1, MSH3, DUC1, DUG |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | MSH3 |
---|---|
Synonyms | DUC1, DUG |
Function | Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS beta which binds to DNA mismatches thereby initiating DNA repair. When bound, the MutS beta heterodimer bends the DNA helix and shields approximately 20 base pairs. MutS beta recognizes large insertion-deletion loops (IDL) up to 13 nucleotides long. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene forms a heterodimer withMSH2 to form MutS beta, part of the post-replicative DNA mismatchrepair system. MutS beta initiates mismatch repair by binding to amismatch and then forming a complex with MutL alpha heterodimer.Defects in this gene are a cause of susceptibility to endometrialcancer.
References
Monsees, G.M., et al. Breast Cancer Res. Treat. 125(1):207-214(2011)Lee, S.Y., et al. Gastroenterology 139(5):1519-1525(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010)Kumarasinghe, A.P., et al. Pathology 42(5):414-420(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.